{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:09:44Z","timestamp":1780110584671,"version":"3.54.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T00:00:00Z","timestamp":1232496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00280-008-0905-5","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T13:13:59Z","timestamp":1232457239000},"page":"195-197","source":"Crossref","is-referenced-by-count":4,"title":["Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?"],"prefix":"10.1007","volume":"64","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stefanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Grammatico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelina","family":"Santopietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"905_CR1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five year follow up of patients receiving imatinib for chronic myeloid leukaemia. New Engl J Med 355:2408\u20132417","journal-title":"New Engl J Med"},{"key":"905_CR2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Mechanisms of resistance to imatinib in chronic myeloid leukaemia (part I and II). Lancet Oncol 8:1018\u20131029","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"905_CR3","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminhematol.2006.12.002","volume":"44","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Erben P, Ernst T et al (2007) Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 44(suppl 1):S15\u2013S24","journal-title":"Semin Hematol"},{"key":"905_CR4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","volume":"13","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Giles F, Quintas-Cardama A, Cortes J (2007) Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13:1089\u20131097","journal-title":"Clin Cancer Res"},{"key":"905_CR5","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O\u2019Brien S et al (2007) Dynamics of BCR\u2013ABL kinase domain mutations in chronic myeloid leukaemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005\u20134011","journal-title":"Blood"},{"key":"905_CR6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D et al (2006) Frequency and clinical significance of BCR\u2013ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767\u20131773","journal-title":"Leukemia"},{"key":"905_CR7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S et al (2003) Detection of BCR\u2013ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 102:276\u2013283","journal-title":"Blood"},{"key":"905_CR8","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","volume":"26","author":"JS Khorashad","year":"2008","unstructured":"Khorashad JS, de Lavallade H, Apperley J, Miloikovic D, Reid AG, Bua M et al (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26:4806\u20134813","journal-title":"J Clin Oncol"},{"key":"905_CR9","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MWN, Druker BJ (2005) In vitro activity of BCR\u2013ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505","journal-title":"Cancer Res"},{"key":"905_CR10","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.2006.08.9128","volume":"24","author":"S Soverini","year":"2006","unstructured":"Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I (2006) Presence or emergence of a F317L BCR\u2013ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 24:e51\u2013e52","journal-title":"J Clin Oncol"},{"key":"905_CR11","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006) Comparison of imatinib mesylate, dasatinib, and nilotinib in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108:2332\u20132338","journal-title":"Blood"},{"key":"905_CR12","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"177","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR\u2013ABL mutations with altered oncogenic potency. J Clin Invest 177:2562\u20132569","journal-title":"J Clin Invest"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0905-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0905-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:56Z","timestamp":1559023616000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0905-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0905-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}